The safety of PCSK9 inhibitors - how low can we go? - PACE-CME

The safety of PCSK inhibitors how low can we go

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Favorable effects of evolocumab on plaque characteristics in severe carotic artery stenosis
Favorable effects of evolocumab on plaque characteristics in severe carotic artery stenosis
ESC Congress 2024
Favorable effects of evolocumab on plaque characteristics in severe carotic artery stenosis
- C. David Mazer, MD
Intensive and early lowering of atherogenic lipids after MI
Intensive and early lowering of atherogenic lipids after MI
ESC Congress 2024
Intensive and early lowering of atherogenic lipids after MI
- Jessica Schubert, MD
Causal relationship between elevated Lp(a) levels and CKD risk
Causal relationship between elevated Lp(a) levels and CKD risk
EAS 2024
Causal relationship between elevated Lp(a) levels and CKD risk
- Anne Langsted, MD, PhD
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
EAS 2024
Bempedoic acid: effective tool in the toolkit for LDL-c lowering
- Stephen Nicholls, FRACP, FACC, FESC, FAHA